Market Place
Sourcing Support
Altimmune To Present New Data On Lipidomic Profile With Pemvidutide
15 Oct 2024 //
GLOBENEWSWIRE
Altimmune Completes Enrollment In IMPACT Trial For Pemvidutide
30 Sep 2024 //
GLOBENEWSWIRE
Altimmune Presents Phase 2 Body Composition Study Results
10 Sep 2024 //
GLOBENEWSWIRE
Altimmune Presents Phase 2 MRI Body Composition Results
10 Sep 2024 //
GLOBENEWSWIRE
Altimmune Publishes Pemvidutide MASLD Study In Hepatology Journal
25 Jul 2024 //
GLOBENEWSWIRE
Altimmune Phase 2 MOMENTUM Trial Pemvidutide Obesity Data ADA 84th Session
23 Jun 2024 //
GLOBENEWSWIRE
Altimmune touts `best-in-class` lean mass results for weight loss therapy
23 Jun 2024 //
FIERCE BIOTECH
Altimmune Announces Pemvidutide Data Presentations At ADA Scientific Sessions
18 Jun 2024 //
GLOBENEWSWIRE
Altimmune: EASL 2024 Data Supports Pemvidutide In MASH
05 Jun 2024 //
GLOBENEWSWIRE
Altimmune`s Pemvidutide Data At EASL Liver Congress 2024
29 May 2024 //
GLOBENEWSWIRE
Altimmune Announces Positive Data for Pemvidutide and Financial Results
27 Mar 2024 //
GLOBENEWSWIRE
Altimmune Announces Presentation of Pemvidutide Clinical Data
02 Jan 2024 //
GLOBENEWSWIRE
Altimmune’s pemvidutide meets weight-loss expectations in study
01 Dec 2023 //
GLOBENEWSWIRE
Altimmune Granted Fast Track Designation by FDA for Pemvidutide
26 Oct 2023 //
GLOBENEWSWIRE
Altimmune to Present New Data on the Anti-Inflammatory Properties of Pemvidutide
25 Oct 2023 //
GLOBENEWSWIRE
Altimmune Announces Oral Presentation of Pemvidutide Clinical Data
26 Sep 2023 //
GLOBENEWSWIRE
Altimmune Announces Completion of Dosing in the Phase 2 Trial of Pemvidutide
12 Sep 2023 //
GLOBENEWSWIRE
Altimmune Announces Initiation of Phase 2b IMPACT Trial Evaluating Pemvidutide
01 Aug 2023 //
GLOBENEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.